JP2021514190A5 - - Google Patents
Info
- Publication number
- JP2021514190A5 JP2021514190A5 JP2020543932A JP2020543932A JP2021514190A5 JP 2021514190 A5 JP2021514190 A5 JP 2021514190A5 JP 2020543932 A JP2020543932 A JP 2020543932A JP 2020543932 A JP2020543932 A JP 2020543932A JP 2021514190 A5 JP2021514190 A5 JP 2021514190A5
- Authority
- JP
- Japan
- Prior art keywords
- mrna sequence
- sequence
- mirna
- isolated mrna
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024015220A JP2024059656A (ja) | 2017-09-07 | 2024-02-02 | コード化リボ核酸の器官保護発現および調節のための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862632056P | 2018-02-19 | 2018-02-19 | |
| US62/632,056 | 2018-02-19 | ||
| USPCT/US2018/049772 | 2018-09-06 | ||
| PCT/US2018/049772 WO2019051100A1 (en) | 2017-09-07 | 2018-09-06 | COMPOSITIONS AND METHODS FOR TARGETED CODING ADMINISTRATION, EXPRESSION AND MODULATION OF RIBONUCLEIC ACIDS IN TISSUE |
| PCT/GB2019/050454 WO2019158955A1 (en) | 2018-02-19 | 2019-02-19 | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024015220A Division JP2024059656A (ja) | 2017-09-07 | 2024-02-02 | コード化リボ核酸の器官保護発現および調節のための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021514190A JP2021514190A (ja) | 2021-06-10 |
| JP2021514190A5 true JP2021514190A5 (https=) | 2022-02-17 |
Family
ID=67619768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543932A Pending JP2021514190A (ja) | 2017-09-07 | 2019-02-19 | コード化リボ核酸の器官保護発現および調節のための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200376142A1 (https=) |
| EP (2) | EP4008333A1 (https=) |
| JP (1) | JP2021514190A (https=) |
| KR (1) | KR20200123139A (https=) |
| CN (1) | CN111954535A (https=) |
| AU (1) | AU2019221826A1 (https=) |
| CA (1) | CA3091543A1 (https=) |
| WO (1) | WO2019158955A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201714430D0 (en) | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| JP7539723B2 (ja) | 2020-02-21 | 2024-08-26 | コンバインド セラピューティクス インコーポレイテッド | コード化リボ核酸の器官保護発現及び調節のための組成物並びに方法 |
| CN113583977B (zh) * | 2020-04-30 | 2025-06-06 | 杭州康万达医药科技有限公司 | 可受微小rna调控的分离的重组溶瘤痘病毒及其应用 |
| MX2023001187A (es) * | 2020-07-31 | 2023-04-04 | Combined Therapeutics Inc | Composiciones y métodos para una vacunación mejorada. |
| CN114908089B (zh) * | 2021-02-08 | 2024-03-15 | 上海细胞治疗集团有限公司 | 3’utr的构建方法和应用 |
| EP4334446A1 (en) | 2021-05-03 | 2024-03-13 | CureVac SE | Improved nucleic acid sequence for cell type specific expression |
| EP4241790A1 (en) * | 2022-03-07 | 2023-09-13 | InnaTher Gene Therapy S.à.r.l. | Expression system for the treatment of cancer |
| EP4241791A1 (en) * | 2022-03-07 | 2023-09-13 | InnaTher Gene Therapy S.à.r.l. | Combined gene and radio therapy for the treatment of cancer |
| CN116334183B (zh) * | 2023-02-18 | 2025-10-21 | 四川大学华西医院 | 基于多重信号放大和金属离子选择性识别现象的尿液中双miRNA的检测方法及其应用 |
| CN116240270A (zh) * | 2023-03-06 | 2023-06-09 | 西北农林科技大学 | 一种动物驯服行为相关rrm1基因突变体的应用 |
| CN117530932B (zh) * | 2024-01-08 | 2024-04-26 | 中国药科大学 | 一种抑制肿瘤生长及肺转移的人工外泌体及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009012263A2 (en) * | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Tissue-specific micrornas and compositions and uses thereof |
| EP3269395A1 (en) | 2008-11-07 | 2018-01-17 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| CA3285826A1 (en) | 2012-02-22 | 2026-03-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| BR112016009465A8 (pt) * | 2013-10-28 | 2018-01-30 | Univ Pittsburgh Commonwealth Sys Higher Education | vetor de hsv oncolítico. |
| CA2955375A1 (en) * | 2014-07-17 | 2016-01-21 | Modernatx, Inc. | Terminal modifications of polynucleotides |
| US11351271B2 (en) * | 2014-09-08 | 2022-06-07 | Massachusetts Institute Of Technology | RNA-based logic circuits with RNA binding proteins, aptamers and small molecules |
| KR20180136435A (ko) | 2016-01-27 | 2018-12-24 | 온코루스, 인크. | 종양 살상형 바이러스 벡터 및 그의 용도 |
| JP7194594B2 (ja) * | 2016-05-18 | 2022-12-22 | モデルナティエックス インコーポレイテッド | 免疫調節ポリペプチドをコードするｍＲＮＡの組み合わせ及びその使用 |
-
2019
- 2019-02-19 EP EP21205379.7A patent/EP4008333A1/en active Pending
- 2019-02-19 CN CN201980013940.5A patent/CN111954535A/zh active Pending
- 2019-02-19 CA CA3091543A patent/CA3091543A1/en active Pending
- 2019-02-19 EP EP19711652.8A patent/EP3755344A1/en active Pending
- 2019-02-19 AU AU2019221826A patent/AU2019221826A1/en not_active Abandoned
- 2019-02-19 WO PCT/GB2019/050454 patent/WO2019158955A1/en not_active Ceased
- 2019-02-19 JP JP2020543932A patent/JP2021514190A/ja active Pending
- 2019-02-19 KR KR1020207024476A patent/KR20200123139A/ko not_active Ceased
- 2019-02-19 US US16/970,888 patent/US20200376142A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021514190A5 (https=) | ||
| Huang et al. | Development of molecular mechanisms and their application on oncolytic Newcastle disease virus in cancer therapy | |
| Xu et al. | Oncolytic vaccinia virus and cancer immunotherapy | |
| Muthukutty et al. | Oncolytic virus engineering and utilizations: cancer immunotherapy perspective | |
| Pol et al. | Trial watch: oncolytic viruses for cancer therapy | |
| Zhang et al. | Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus | |
| US12220456B2 (en) | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids | |
| Jebar et al. | Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma | |
| JP2020533411A5 (https=) | ||
| Malhotra et al. | Oncolytic viruses and cancer immunotherapy | |
| EP3566709B1 (en) | Therapeutic agents comprising oncolytic vaccinia viruses and nk cells, and uses thereof for drugs for treatment of tumors and/or cancers | |
| CN115624524B (zh) | Peg化白蛋白修饰的溶瘤病毒静脉递送制剂的制备及其应用 | |
| Duan et al. | Oncolytic Virus‐Driven Biotherapies From Bench to Bedside | |
| Nisar et al. | An extensive review on preclinical and clinical trials of oncolytic viruses therapy for pancreatic cancer | |
| RU2020112990A (ru) | Композиции и процессы для направленной доставки, экспрессии и модуляции кодирующих рибонуклеиновых кислот в ткани | |
| Apostolidis et al. | Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application | |
| Omole et al. | Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy | |
| Kenoosh et al. | Recent advances in mRNA‐based vaccine for cancer therapy; bench to bedside | |
| Bahreyni et al. | A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy | |
| Ding et al. | An Inter‐Supplementary Biohybrid System Based on Natural Killer Cells for the Combinational Immunotherapy and Virotherapy of Cancer | |
| Huang et al. | Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus | |
| Yuan et al. | The investigation of oncolytic viruses in the field of cancer therapy | |
| CN119736261A (zh) | 溶瘤病毒及其应用 | |
| CN116196437A (zh) | 红细胞负载溶瘤病毒静脉递送制剂的制备及其抗肿瘤应用 | |
| Yang et al. | The role of mesenchymal stem cells and exosomes in tumor development and targeted antitumor therapies |